| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68001-0359-37 | 68001-0359 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 25, 2018 | In Use | |
| 61703-0155-01 | 61703-0155 | CYTARABINE | Cytarabine | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Apr 7, 2025 | In Use | |
| 54868-5260-02 | 54868-5260 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jun 28, 2005 | In Use | |
| 16714-0909-01 | 16714-0909 | Gemcitabine Hydrochloride | Gemcitabine | 200.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Nov 1, 2018 | In Use | |
| 00004-1101-75 | 00004-1101 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 30, 1998 | Dec 31, 2014 | No Longer Used |
| 68001-0525-27 | 68001-0525 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb 18, 2022 | In Use | |
| 00004-1101-50 | 00004-1101 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 30, 1998 | Jul 31, 2025 | No Longer Used |
| 00179-0149-70 | 00179-0149 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | May 14, 2014 | Mar 31, 2016 | In Use |
| 68083-0149-01 | 68083-0149 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb 1, 2016 | In Use | |
| 72572-0020-01 | 72572-0020 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Sep 12, 2025 | In Use | |
| 50742-0481-20 | 50742-0481 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 21, 2019 | In Use | |
| 50742-0496-26 | 50742-0496 | gemcitabine | GEMCITABINE | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 1, 2023 | In Use | |
| 59923-0722-12 | 59923-0722 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 1, 2020 | In Use | |
| 68001-0282-27 | 68001-0282 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 23, 2016 | Aug 1, 2021 | No Longer Used |
| 43598-0348-37 | 43598-0348 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 11, 2013 | In Use | |
| 71288-0117-93 | 71288-0117 | Gemcitabine hydrochloride | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 11, 2020 | In Use | |
| 50419-0208-01 | 50419-0208 | Radium Ra 223 dichloride | Xofigo | 30.0 uCi/mL | Chemotherapy | Radiopharmaceutical | Radium 223 | Intravenous | May 20, 2013 | In Use | |
| 55513-0710-21 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Mar 5, 2024 | In Use | |
| 55513-0730-21 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Apr 15, 2025 | In Use | |
| 70121-2701-01 | 70121-2701 | Denosumab-mobz | Oziltus | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Dec 23, 2025 | In Use | |
| 55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 5, 2010 | In Use | |
| 65219-0668-01 | 65219-0668 | Denosumab | CONEXXENCE | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 30, 2025 | In Use | |
| 61314-0228-94 | 61314-0228 | Denosumab | WYOST | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 78206-0193-01 | 78206-0193 | Denosumab | BILDYOS | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 11, 2025 | In Use | |
| 70121-2702-01 | 70121-2702 | Denosumab-mobz | Boncresa | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Dec 23, 2025 | In Use |
Found 12159 results — Export these results
Home